EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Reasons for Discontinuation of Obesity Pharmacotherapy With Semaglutide or Tirzepatide in Clinical Practice

Hamlet Gasoyan iD, W Scott Butsch iD, Nicholas J Casacchia, Rebecca Schulte, Victoria Criswell, Jacqueline Fox, Holly Renner, Phuc Le, Jordan Alpert, Michael B Rothberg

Obesity · 2025-12 · 33 (12) · 2296-2303

DOI: 10.1002/oby.70058 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Obesity, online erschienen am 02.10.2025. Verfasst von Hamlet Gasoyan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Center for Value-Based Care Research, Department of Internal Medicine and Geriatrics, Primary Care Institute, Cleveland Clinic, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Obesity, Tirzepatide, Anti-Obesity Agents. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Cleveland Clinic Research Program Committees.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study aimed to characterize the reasons for treatment discontinuation with injectable semaglutide or tirzepatide for obesity in regular clinical practice.

Methods

This cross‐sectional study used electronic health record data between January 2022 and December 2024 from a single integrated health system in Ohio and Florida. The primary reason for treatment discontinuation was examined in a randomly selected sample of adults with overweight or obesity and without type 2 diabetes who initiated injectable semaglutide or tirzepatide and discontinued treatment within the first year.

Results

We randomly selected 288 patients; 145 received semaglutide and 143 tirzepatide. Overall, 137 patients (47.6%) discontinued their medication due to cost or insurance‐related issues, 42 (14.6%) due to inability to tolerate the side effects, 34 (11.8%) as they were unable to fill the medication due to shortages, 7 (2.4%) as they switched to a compounded medication, and 5 (1.7%) due to unsatisfactory weight loss; 31 (10.8%) discontinued for other reasons, and for 32 (11.1%) patients the discontinuation reason was not specified in the electronic health record.

Conclusions

High cost or insurance‐related issues are the most common reasons for treatment discontinuation with semaglutide or tirzepatide for obesity. Our findings highlight the need for policies to address cost and could inform discussions between healthcare providers and patients concerning cost and side effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like PeptidesObesityTirzepatideAnti-Obesity AgentsHumansMaleFemaleMiddle AgedCross-Sectional StudiesAdultAgedDiabetes Mellitus, Type 2OhioFloridaElectronic Health RecordsGlucagon-Like Peptide 1Semaglutide

Stichwörter der Autor:innen

glucagon‐like peptide‐1 receptor agonistsobesity pharmacotherapytreatment discontinuation

Substanzen

Glucagon-Like PeptidesTirzepatideAnti-Obesity AgentsGlucagon-Like Peptide 1Semaglutide

Autor:innen und Institutionen

  • Center for Value-Based Care Research, Department of Internal Medicine and Geriatrics, Primary Care Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • Department of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
  • Department of Surgery, Bariatric and Metabolic Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • Department of Internal Medicine and Geriatrics, Primary Care Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, USA.

ORCID-Profile: Hamlet Gasoyan, W Scott Butsch

Förderung

  • Cleveland Clinic Research Program Committees

Zitieren

APA

Gasoyan, H., Butsch, W. S., Casacchia, N. J., Schulte, R., Criswell, V., Fox, J., Renner, H., Le, P., Alpert, J., & Rothberg, M. B. (2025). Reasons for Discontinuation of Obesity Pharmacotherapy With Semaglutide or Tirzepatide in Clinical Practice. Obesity, 33(12), 2296-2303. https://doi.org/10.1002/oby.70058

Vancouver

Gasoyan H, Butsch WS, Casacchia NJ, Schulte R, Criswell V, Fox J, et al. Reasons for Discontinuation of Obesity Pharmacotherapy With Semaglutide or Tirzepatide in Clinical Practice. Obesity. 2025;33(12):2296-2303. doi:10.1002/oby.70058

BibTeX
@article{Gasoyan2025,
  author = {Gasoyan, Hamlet and Butsch, W Scott and Casacchia, Nicholas J and Schulte, Rebecca and Criswell, Victoria and Fox, Jacqueline and Renner, Holly and Le, Phuc and Alpert, Jordan and Rothberg, Michael B},
  title = {Reasons for Discontinuation of Obesity Pharmacotherapy With Semaglutide or Tirzepatide in Clinical Practice},
  journal = {Obesity},
  year = {2025},
  volume = {33},
  number = {12},
  pages = {2296--2303},
  doi = {10.1002/oby.70058}
}
Kostenlos starten →